The complaint, filed in the U.S. District Court for the Central District of California as Holtzman v. Beta Bionics, Inc., accuses the firm and its executives of violating federal securities laws. Central to the case are claims that Beta Bionics ignored over 18,000 user complaints regarding the iLet device, many involving life-threatening hypoglycemia caused by the system’s aggressive insulin dosing algorithm. These issues allegedly surfaced in a June 2025 FDA Form 483, yet the company continued to tout the device’s clinical success to the market.
Beta Bionics Faces Class Action Over Alleged iLet Safety Failures
Investors have until November 3, 2026, to join a class action lawsuit against Beta Bionics, Inc., following allegations that the company misled stakeholders regarding the safety and performance of its iLet insulin delivery system. The litigation follows a sharp 37% decline in the company’s stock price earlier this year.
Financial fallout for shareholders intensified in early 2026. On January 8, the company disclosed that new patient enrollments missed analyst projections by nearly 10%, triggering a 37% drop in share value. Market pressure persisted into February 2026, when the FDA publicly released a warning letter confirming that the company failed to report malfunctions linked to patient injury. Law firm Bleichmar Fonti & Auld LLP is representing the plaintiffs, seeking to hold the company accountable for what they describe as a pattern of misrepresentation regarding the device's autonomous safety features.
Comments (0)
No comments yet. Be the first!